Breast lymphoma: favorable prognosis after treatment with standard combination chemotherapy

Onkologie
Su-Pin ChooMiriam Tao

Abstract

This paper is to determine the clinicopathological features and outcome of patients with breast lymphoma seen at a single institution. We have reviewed data on 14 patients with breast lymphoma seen at our institution from 1990 to 2003. All patients were female, with a median age of 47.6 years. Diffuse large B-cell lymphoma (DLBCL) was observed in 9 cases, while follicular, Burkitt's, small lymphocytic, MALT and T-cell lymphoma were observed in 1 case each. 5 patients (35.7%) had stage IE disease, 6 patients (42.9%) had stage IIE disease and 3 patients (21.4%) had stage IV disease. Standard CHOP with or without rituximab was given to all patients with aggressive breast lymphoma (n = 10), while 1 patient with Burkitt's lymphoma received a CHOP-based regimen. The 3-year actuarial survival estimate among all 11 patients with aggressive breast lymphoma was 73%. Among those with localized disease, the estimated 3-year survival was 90%. The actuarial 3-year overall survival (OS) estimate for the entire cohort of 14 patients was 76.9%. Our results indicate that breast lymphoma is not associated with an inferior outcome when treated with standard CHOP-based chemotherapy.

References

Feb 1, 1992·Cancer·R GiardiniF Rilke
Feb 1, 1987·Annals of Surgery·S BrusteinP P Rosen
Mar 1, 1987·The British Journal of Surgery·J M DixonT J Anderson
Jun 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J I BernsteinS A Rosenberg
Jun 1, 1972·Cancer·C Wiseman, K T Liao
Dec 1, 1981·Annals of Surgery·J T SchoutenP P Carbone
Jan 1, 1996·Pathology, Research and Practice·S L AbbondanzoJ Krishnan
Feb 1, 1997·Hematological Oncology·W Y AuR Liang
Jun 20, 2000·Acta Oncologica·I BariştaD Firat
Aug 24, 2000·American Journal of Clinical Oncology·J A LyonsR L Crownover
Jan 30, 2002·Cancer·Susan M DomchekGeorge P Canellos
Apr 22, 2003·Cancer Chemotherapy and Biological Response Modifiers·Armando SantoroLuca Castagna
Aug 15, 2003·Leukemia & Lymphoma·D GholamV Ribrag
Nov 1, 1962·Cancer·J J DECOSSEJ H FARROW
Jan 30, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Julie M VoseMary M Horowitz
Apr 23, 2004·Leukemia & Lymphoma·Yeon Hee ParkSeung-Sook Lee
Oct 20, 2004·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Sayaka YoshidaMasafumi Abe

❮ Previous
Next ❯

Citations

Sep 18, 2008·Archives of Gynecology and Obstetrics·Philipp LingohrKarl Peter Rheinwalt
Apr 17, 2008·International Journal of Hematology·Hai-Yi GuoXi-Chun Hu
Jul 3, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G MartinelliF Cavalli
Mar 8, 2007·Onkologie·David B GeffenMichael Koretz
Nov 27, 2007·World Journal of Surgical Oncology·Shigeyuki NagataKenzo Wakasugi
Apr 2, 2011·Clinical Lymphoma, Myeloma & Leukemia·Shu ZhaoXiao-Chuan Wang
Nov 10, 2015·Indian Journal of Pathology & Microbiology·Jianguo WeiCheng Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.